European Pharma in Flux: Orion Bets on R&D Growth as Global Restructuring Reshapes EU Drug Pipelines
Finland's Orion Corporation is forecasting increased R&D investment and revenue of up to €2.1 billion in 2026, signalling confidence in the European pharmaceutical landscape even as global giants restructure their operations. The broader sector is navigating a complex convergence of regulatory approvals, corporate realignments, and pipeline expansions that carry significant implications for EU-based research and drug development. European regulators and investors alike are watching closely as po
ViaNews Editorial Team (Europe)•